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Objectives: MRSA is being increasingly cultured from the respiratory tract of
patients with CF. This study aimed to characterize MRSA isolates cultured from
paediatric CF patients in Northern Ireland and the USA to study epidemiology in
different centers.
Methods: 22 isolates cultured from 21 patients attending the Belfast Paediatric CF
centre (BPCF), and 11 isolates cultured from 7 patients attending the CF centre
at the University of North Carolina (UNC), were compared. MRSA isolates were
characterized by typing of the SCCmec complex and pulsed ﬁeld gel electrophoresis
(PFGE) and analysis of banding patterns. Presence of the PVL gene in each isolate
was determined by PCR.
Results: All isolates cultured from CF patients in Belfast were SCCmec IV, whilst
UNC isolates were SCCmec II (n = 8) or IV (n = 3). By PFGE, all BPCF isolates
except 1, formed a distinct cluster of >60% similarity. The UNC isolates and the
remaining BPCF isolate, also formed a cluster of >70% similarity to each other,
but with <50% similarity to the BPCF isolates. BPCF isolates included isolates
from 2 sibling pairs; one pair were identical, with exact banding pattern matches,
while the other pair had a one-band difference. Furthermore, duplicate isolates
from one patient, obtained 18 months apart, were similar, but not identical (a 2-band
difference). No BPCF isolates were PVL positive, but isolates from 2 UNC patients
were.
Conclusion: This study highlights the need for further molecular epidemiological
studies on MRSA isolates obtained from CF patients, to more accurately determine
prevalent MRSA strains.
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MRSA is increasingly recognized in health-care associated (HA-MRSA) and
community-acquired (CA-MRSA) infections. Recently, there has been an alarming
epidemic and severe infections caused by CA-MRSA. The characterization of
CA-MRSA and HA-MRSA is based on SCCmec typing, however the genetic
background of MRSA strains isolated from CF patients is not known. Forty-nine CF
patients attending the CF center of Florence infected by MRSA have been studied.
Eight out of 49 patients were persistently infected by MRSA and the median lenght
of the infection period was 6 years (range 4−10 years). Forty-four MRSA (one
strains/year) have been collected from these 8 patients and all have been analysed
to assess their SCCmec type. Five out of 8 patients were persistently colonized by
HA-MRSA (SCCmec I); 3 patients were mostly colonized by HA-MRSA (SCCmec
I) but experienced infection period (from 1 to 2 years) with CA-MRSA (SCCmec
IV). These data show that HA-MRSA accounted for most of persistent infections
in studied CF patient.CA-MRSA were not responsible for persistent infections,
probably they are cleared due to their good susceptibility to antibiotics. In spite
of worrysome evidence regarding pathogenic potential of CA-MRSA strains in
different settings included the CF population, only HA-MRSA are responsible for
prolonged infection periods. Recent ﬁndings demonstrated the correlation between
persistent infection with MRSA and a more rapid rate of decline in lung function,
therefore the genetic background of MRSA involved in log term infections should
be further investigated
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Methicillin-resistant S. aureus (MRSA) is a public health problem due to the increas-
ing rate of infection in several settings as well as in CF patients. MRSA was ﬁrst
recognized as being acquired from hospitalised patients (HA-MRSA), but the onset
of MRSA infection outside the hospital setting, in community-associated strains
(CA-MRSA), has been described with increasing frequency. CA-MRSA strains
are replacing HA-MRSA strains and causing severe infections. Characterisation of
the SCCmec cassette is needed to properly estimate the prevalence of CA-MRSA.
However, data is limited regarding the genetic background of these pathogens in
the CF population. An Italian study investigates epidemiology, SCCmec type and
clinical impact of MRSA strains isolated from nine Italian CF centres. MRSA strains
(n = 178) were collected from 178 out of 2362 (7.5%) patients. A high prevalence
(36%) of CA-MRSA (SCCmec IV) strains was found. Preliminary data showed that
the mean age of the ﬁrst infection was 11.8 years and 19.2 years in patients infected
by CA-MRSA (n = 28) and in patients infected by HA-MRSA (n = 37) respectively.
This difference was statistically signiﬁcant (p< 0.05). These ﬁndings show that
CA-MRSA is now widespread also in CF population. CA-MRSA strains lead to an
earlier onset of the ﬁrst pulmonary infection compared with HA-MRSA. This data
could have important implications for prevention and treatment of infection of such
potentially pathogenic strains in CF patients.
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Objective: To identify CF patients with a detection of methicillin resistant Staphylo-
coccus aureus (MRSA) since 1998 and to assess the measures taken for eradication
of this organism.
Patients: All microbiological results from all 505 CF patients who were followed
at the Munich CF centre since 1998 were analysed focusing on the detection of
MRSA.
Methods: Retrospective chart analysis of MRSA positive CF patients regarding
eradication outcome.
Results: We identiﬁed 29 patients with a MRSA detection (5.7%), mean age
17.1±11 years (range: 0.8 to 38), consequently giving an overall incidence of 0.5
per 100 CF patients per year. Eradication was suggested to all patients, however
only 26 gave their consent to the following approach: screening of patients and close
contact persons (swabs from nose, throat, axilla, inguinal, perineal) and subsequent
eradication therapy according to resistance using a combined dual iv antibiotic
treatment accompanied by hygienic directives and topic therapy over 3 weeks. This
was followed by a 6 week period with double oral antibiotic therapy and additional
inhalation with vancomycin. Positive contact persons were treated over a 3 weeks
period topically and orally. 24 of these 26 patients were followed for more than
6 months: eradication was successful in 21 of 24 patients (87%).
Conclusion: Although MRSA detection usually is not accompanied by clinical
signs of deterioration it implicates hygienic measures of complex and expensive
nature which often are not well accepted by patients. Despite the universal increase
of MRSA, eradication of this organism therefore is reasonable. Aggressive therapy
regimens may be successful to eradicate MRSA in patients with CF and established
lung disease.
